Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P 53 mutations in bladder cancer

Pharmacogenetics

Volumn 6, Issue 6, 1996, Pages 535-545

  Brockmöller, Jürgen ^a   Kaiser, Rolf ^a   Kerb, Reinhold ^a   Cascorbi, Ingolf ^a   Jaeger, Viola ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bladder cancer; Metabolic polymorphisms; p53 mutations

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 ISOENZYME; DNA; DRUG METABOLIZING ENZYME; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; BLADDER CANCER; BLOOD CELL; CLINICAL TRIAL; DETOXIFICATION; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; POINT MUTATION; PRIORITY JOURNAL; SMOKING; TUMOR SUPPRESSOR GENE; XENOBIOTIC METABOLISM;

ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; EPOXIDE HYDROLASES; GENES, P53; GLUTATHIONE TRANSFERASE; HUMANS; METABOLIC DETOXICATION, DRUG; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; URINARY BLADDER NEOPLASMS; XENOBIOTICS;

EID: 0030477974     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199612000-00007     Document Type: Article

References (50)

1. Ayesh R, Idle JR, Ritchi JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984: 312, 169-171.
2. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993: 85, 1159-1164.
3. Branch RA, Chern HD, Adedoyin A, Romkes-Sparks M, Lesnick TG, Persad R, Wilkinson GR, Fleming CM, Dickinson AJ, Sibley G and Smith P. The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 1995: 5, S97-S102.
4. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin JA, Pontén J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991: 88, 10124-10128.
5. Brockmöller J, Kerb R, Drakoulis N, Staffeldt B, Roots I. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res 1994: 54, 4103-4111.
6. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined genetical analysis of arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, and cytochrome P450 enzymes as hereditable modulators of bladder cancer risk. Cancer Res 1996: 56, 3915-3925.
7. Cartwright RA, Glashan RW, Rogers HJ, Ahmod RA, Barham-Hall D, Higgins F, Kahn MA. The role of N-acetyltransferase in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982: ii, 842-845.
8. Caporaso N, Landi MT, Vineis P. Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics 1991: 1, 4-19.
9. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Human Genetics 1995: 57, 581-592.
10. Cascorbi I, Brockmöller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and the impact to lung cancer susceptibility. Cancer Res 1996, 56, 4965-4969.
11. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P450 2D6. Carcinogenesis 1991: 12, 1197-1201.
12. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingleman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert D, Steen V, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996: 6, 193-201.
13. Drakoulis N, Cascorbi I, Brockmöller J, Gross CR, Roots I. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Invest 1994: 72, 240-248.
14. Evans PDA. N-Acetyltransferase. In: W. Kalow, ed. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 95-178.
15. Fernandez-Salguero P, Hoffman SMG, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang J-D, Evans WE, Idle JR, Gonzalez FJ. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995: 57, 651-660.
16. Fujimoto K, Yamada Y, Okayima E, Kakizoe T, Sasaki H, Sugimura T, Terada M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992: 52, 1393-1398.
17. Greenblatt IS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to etiology and molecular pathogenesis. Cancer Res 1994: 54, 4855-4878.
18. Grinberg-Funes RA, Singh VN, Perera FP, Bell DA, Young TL, Dickey C, Wang LW, Santella RM. Polycyclic aromatic hydrocarbon - DNA adducts in smokers and their relationship to the micronutrient levels and the glutathione-S-transferase M1 genotype. Carcinogenesis 1994: 15, 2449-2454.
19. Guengerich FP, Kim D-H, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991: 4, 168-179.
20. Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K, Hamazaki S, Toguchida J, Ishizaki K, Fujita J, Sugiyama T, Yoshida O. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 1993: 53, 3795-3799.
21. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism functional expression in vitro of amino acid variants. Human Mol Genet 1994: 3, 421-428.
22. Hayashi SI, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change translational regulation of the human cytochrome P450IIE1 gene. J Biochem 1991: 110, 559-565.
23. Hirvonen A, Nylund L, Kociba P, Husgafvel-Pursianinen K, Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis 1994: 15, 813-815.
24. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991: 350, 427-428.
25. Idle JR. Is environmental carcinogenesis modulated by host polymorphism? Mutat Res 1991: 247, 259-266.
26. Jones PA, Buckley JD, Henderson BE, Ross RK, Pike MC. From gene to carcinogen: a rapidly evolving field in molecular epidemiology. Cancer Res 1991: 51, 3617-3620.
27. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S-I. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 1993: 14, 77-87.
28. Li FP, Montesano R. Interactions of cancer susceptibility genes and environmental carcinogens. Cancer Res 1994: 54, 4243-4247.
29. Lasko DD, Harvey SC, Malaikal SB, Kadlubar FF, Essigmann JM. Specificity of mutagenesis by 4-aminobiphenyl. A possible role for N-(deoxyadenosin-8-yl)-4-aminobiphenyl as a premutational leson. J Biol Chem 1988: 263, 15429-15435.
30. Lehmann T, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appella E, Testa JR, Gerwin BI, Harris CC. P53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991: 51, 4090-4096.
31. McGlynn K, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou T, Wild CP, Xia X-L, Baffoe-Bonnie A, Ofori-Adjei D, Chen G-C, London WT, Shen F-M, Buetow KH. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA 1995: 92, 2384-2387.
32. Ohgaki H, Hard GC, Hirota N, Maekawa A, Takahashi M, Kleihues P. Selective mutation of codons 204 and 213 of the p53 gene in rat tumours induced by alkylating N-nitroso compounds. Cancer Res 1992: 52, 2995-2998.
33. Ozturk M, and Collaborators. P53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991: 338, 1356-1359.
34. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. Human glutathione S-transferase Theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994: 300, 271-276.
35. Reardon DB, Bigger CAH, Dipple A. DNA polymerase action on bulky deoxyguanosine and doxyadenosine adducts. Carcinogenesis 1990: 11, 165-168.
36. Risch A, Wallace DMA, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995: 4, 231-236.
37. Roots I, Drakoulis N, Brockmöller J. Polymorphic enzymes and cancer risk: concepts, methodology and data review. In: W Kalow, ed., Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 815-841.
38. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, Børrensen A-L, Haugen A. P53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res 1994: 54, 1551-1555.
39. Seidegård J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988: 85, 7293-7297.
40. Shields PG, Bowman ED, Harrington AM, Doan VT, Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res 1993: 53, 3486-3492.
41. Sidransky U, von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Mershal IF, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B. Identification of p53 gene mutations in bladder cancer and urine samples. Science 1991: 252, 706-709.
42. Spruck CH, Rideout WM, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, Ross RK, Yu C, Jones PA. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res 1993: 53, 1162-1166.
43. Thier R, Taylor JB, Pemble SE, Humphreys WG, Persmark M, Ketterer B, Guengerich FP. Expression of mammalian glutathione S-transferase 5-5 in Salmonella typhimurium TA1535 leads to base-pair mutations upon exposure to dihalomethanes. Proc Natl Acad Sci USA 1993: 90, 8576-8580.
44. Umeno M, McBride WO, Yang CS, Gelboin HV, Gonzalez FJ. Human ethanol-inducible P450IIE1: complete gene sequence, promotor characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 1988: 27, 9006-9013.
45. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Evans DAP, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y. Nomenclature of N-acetyltransferases. Pharmacogenetics 1995: 5, 1-17.
46. Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM, Schalken JA. P53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 1994: 70, 496-500.
47. Vineis P, Caporaso N, Tannenbaum SR, Skipper PL, Glogowski, Bartsch H, Coda M, Talaska G, Kadlubar F. Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette smoking. Cancer Res 1990: 50, 3002-3004.
48. Vogelstein B, Kinzler KW. Carcinogens leave fingerprints. Nature 1992: 355, 209-210.
49. Wiencke JK, Kelsey KT, Lamela RA, Roscano WA. Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Res 1990: 50, 1585-1590.
50. Wood ML, Essigmann JM. Molecular mechanisms by which carcinogen-DNA adducts cause mutations. In: J Brugge. T Curran, E Harlow, F McCormic, eds. Origins of human cancer. A comprehensive review. Cold Spring Harbor., NY: Cold Spring Harbor Laboratory Press, 1991: 137-151.